{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:41:13Z","timestamp":1781710873461,"version":"3.54.5"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients with severe OCS-dependent asthma can be considered a subgroup of asthma patients with severe disease and great risk of complications, related to chronic OCS use. The introduction of biological drugs has represented a turning point in the therapeutic strategy for severe asthma, offering a valid alternative to OCS. Benralizumab, like other anti-IL-5 agents, has been shown to reduce exacerbations and OCS intake\/dosage and improve symptom control and lung function. While these findings have also been confirmed in real-life studies, data on long-term efficacy are still limited. Methods: In this retrospective study, we evaluated the effects of 2 years of treatment with benralizumab on 44 patients with OCS-dependent severe asthma by analyzing clinical, biological and functional data. Results: After 2 years of benralizumab, 59.4% discontinued OCS and patients who continued to use OCS had their mean dose reduced by approximately 85% from baseline. Meanwhile, 85% of patients had their asthma well-controlled (ACT score &gt; 20) and had no exacerbations, and 41.6% had normal lung function. Conclusions: Our findings support the long-term effectiveness of benralizumab in severe OCS-dependent asthma in a real-life setting, suggesting potential reductive effects on costs and complications such as adverse pharmacological events.<\/jats:p>","DOI":"10.3390\/jcm12030985","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T11:19:53Z","timestamp":1675077593000},"page":"985","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting"],"prefix":"10.3390","volume":"12","author":[{"given":"Carolina","family":"Vitale","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84100 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1874-1686","authenticated-orcid":false,"given":"Angelantonio","family":"Maglio","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84100 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-7367","authenticated-orcid":false,"given":"Corrado","family":"Pelaia","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"D\u2019Amato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Federico II University, 80100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Ciampo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84100 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pelaia","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Molino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Federico II University, 80100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8265-3037","authenticated-orcid":false,"given":"Alessandro","family":"Vatrella","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry \u201cScuola Medica Salernitana\u201d, University of Salerno, 84100 Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"ref_1","unstructured":"(2022, December 14). 2022 GINA Main Report. Available online: https:\/\/ginasthma.org\/gina-reports\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4168\/aair.2022.14.4.412","article-title":"Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment From the Korean Severe Asthma Registry (KoSAR)","volume":"14","author":"Lee","year":"2022","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of Long-Term Oral Corticosteroid Therapy and Its Side-Effects in Severe Asthma in Adults: A Focused Review of the Impact Data in the Literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1900804","DOI":"10.1183\/13993003.00804-2019","article-title":"Increased Mortality in Patients with Corticosteroid-Dependent Asthma: A Nationwide Population-Based Study","volume":"54","author":"Lee","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12931-017-0614-x","article-title":"The Cost of Systemic Corticosteroid-Induced Morbidity in Severe Asthma: A Health Economic Analysis","volume":"18","author":"Barry","year":"2017","journal-title":"Respir. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/23808993.2020.1776106","article-title":"Phenotyping Severe Asthma: A Rationale for Biologic Therapy","volume":"5","author":"Vatrella","year":"2020","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pelaia, C., Pelaia, G., Crimi, C., Maglio, A., Stanziola, A.A., Calabrese, C., Terracciano, R., Longhini, F., and Vatrella, A. (2022). Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines, 10.","DOI":"10.3390\/biomedicines10051064"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Vatrella, A., Maglio, A., Pelaia, C., Ciampo, L., Pelaia, G., and Vitale, C. (2022). Eosinophilic Inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092181"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/cea.13885","article-title":"Treating Severe Asthma: Targeting the IL-5 Pathway","volume":"51","author":"Principe","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3389\/fmed.2017.00135","article-title":"Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma","volume":"4","author":"Bagnasco","year":"2017","journal-title":"Front. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4839230","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma","volume":"2018","author":"Pelaia","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and Safety of Benralizumab for Patients with Severe Asthma Uncontrolled with High-Dosage Inhaled Corticosteroids and Long-Acting \u03922-Agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an Anti-Interleukin-5 Receptor \u03b1 Monoclonal Antibody, as Add-on Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years","volume":"9","author":"Korn","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral Corticosteroid Elimination via a Personalised Reduction Algorithm in Adults with Severe, Eosinophilic Asthma Treated with Benralizumab (PONENTE): A Multicentre, Open-Label, Single-Arm Study","volume":"10","author":"Gurnell","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"101830","DOI":"10.1016\/j.pupt.2019.101830","article-title":"Real-Life Rapidity of Benralizumab Effects in Patients with Severe Allergic Eosinophilic Asthma: Assessment of Blood Eosinophils, Symptom Control, Lung Function and Oral Corticosteroid Intake after the First Drug Dose","volume":"58","author":"Pelaia","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2050313X20906963","DOI":"10.1177\/2050313X20906963","article-title":"Effects of the First Three Doses of Benralizumab on Symptom Control, Lung Function, Blood Eosinophils, Oral Corticosteroid Intake, and Nasal Polyps in a Patient with Severe Allergic Asthma","volume":"8","author":"Pelaia","year":"2020","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of ItaliaN Severe Uncontrolled Asthmatic PatieNts Key Features When Receiving Benralizumab in a Real-Life Setting: The Observational REtrospective ANANKE Study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir. Res."},{"key":"ref_24","first-page":"7461","article-title":"Severe Asthma and Long-Term Benralizumab Effectiveness in Real-Life","volume":"26","author":"Sposato","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1445-5994.2010.02192.x","article-title":"Corticosteroid Insensitivity in Severe Asthma: Significance, Mechanisms and Aetiology","volume":"40","author":"Hew","year":"2010","journal-title":"Intern. Med. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1378\/chest.08-0440","article-title":"Molecular Mechanisms of Corticosteroid Resistance","volume":"134","author":"Adcock","year":"2008","journal-title":"Chest"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110444","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-Life Effects of Benralizumab on Exacerbation Number and Lung Hyperinflation in Atopic Patients with Severe Eosinophilic Asthma","volume":"129","author":"Pelaia","year":"2020","journal-title":"Biomed. Pharmacother. Biomedecine Pharmacother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Maglio, A., Vitale, C., Pellegrino, S., Calabrese, C., D\u2019Amato, M., Molino, A., Pelaia, C., Triggiani, M., Pelaia, G., and Stellato, C. (2021). Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111550"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12325-019-01191-2","article-title":"Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma","volume":"37","author":"Jackson","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of Effect and Impact on Health-Related Quality of Life, Exacerbation Rate, Lung Function, and Nasal Polyposis Symptoms for Patients with Severe Eosinophilic Asthma Treated with Benralizumab (ANDHI): A Randomised, Controlled, Phase 3b Trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline Patient Factors Impact on the Clinical Efficacy of Benralizumab for Severe Asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of Enhanced Response with Benralizumab for Patients with Severe Asthma: Pooled Analysis of the SIROCCO and CALIMA Studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/S2213-2600(21)00487-2","article-title":"Adrenal Insufficiency in Patients Taking Benralizumab as Corticosteroid Sparing Therapy","volume":"10","author":"Lipworth","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_35","first-page":"1243","article-title":"Low-Dose Adrenocorticotropin Test Reveals Impaired Adrenal Function in Patients Taking Inhaled Corticosteroids","volume":"80","author":"Broide","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Delphi Panel Defining a Severe Asthma Super-Responder: Findings from a Delphi Process","volume":"9","author":"Upham","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/985\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:17:31Z","timestamp":1760120251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12030985"],"URL":"https:\/\/doi.org\/10.3390\/jcm12030985","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}